Brief: Compass Pathways Says FDA Granted NDA Rolling Review Request & Awarded Commissioner's National Priority Voucher
24/04/2026 17:28
April 24 (Reuters) - Compass Pathways PLC CMPS.O: COMPASS PATHWAYS ANNOUNCES FDA GRANTED NDA ROLLING REVIEW REQUEST AND AWARDED COMMISSIONER'S NATIONAL PRIORITY VOUCHER COMPASS PATHWAYS PLC - AWARDED CNPV FOR COMP360 FOR TREATMENT-RESISTANT DEPRESSION COMPASS PATHWAYS PLC - CNPV PROGRAM PROVIDES SHORTENED 1-2 MONTH REVIEW TIME AFTER NDA FILING Source text: ID:nBwc808GGa Further company coverage: CMPS.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on COMPASS Pathways
See all newsCompass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Corrected: Compass Pathways Q3 net loss narrows on lower R&D charges
Corrected: BRIEF-COMPASS Pathways Q3 EPS USD -0.31
Psychedelic drug developers fall after Usona submits depressive drug application
Compass Pathways PLC expected to post a loss of 45 cents a share - Earnings Preview